UK markets closed
NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.85 +0.83 (+1.06%) GOLD FUTURES
2,392.70 +32.80 (+1.39%) DOW
39,908.07 +349.96 (+0.88%) Bitcoin GBP
52,036.12 +3,498.01 (+7.21%)
PTCT May 2024 29.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:45PM EDT. Market open.
| Previous close | 2.5000 |
| Open | 2.5000 |
| Bid | 1.0500 |
| Ask | 3.9000 |
| Strike | 29.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.5000 - 2.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 15 |
PR NewswirePTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
Investor's Business DailyPTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
© 2024 Yahoo. All rights reserved.